3,3'-((4R,7S,10S,13S,16S,19R)-19-((S)-2-amino-3-(4-hydroxyphenyl)propanamido)-4-((6S,9S,12S,15S)-1-amino-9-sec-butyl-6-carboxy-16-(4-hydroxyphenyl)-1-imino-12-isobutyl-8,11,14-trioxo-2,7,10,13-tetraazahexadecan-15-ylcarbamoyl)-7-benzyl-13-sec-butyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-10,16-diyl)dipropanoic acid

ID: ALA4165601

Chembl Id: CHEMBL4165601

PubChem CID: 145953077

Max Phase: Preclinical

Molecular Formula: C67H96N14O18S2

Molecular Weight: 1449.72

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  CC[C@H](C)[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc2ccccc2)C(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O

Standard InChI:  InChI=1S/C67H96N14O18S2/c1-7-36(5)54-64(96)73-44(24-26-52(84)85)57(89)76-48(31-38-13-10-9-11-14-38)60(92)79-51(34-101-100-33-50(62(94)72-45(58(90)80-54)25-27-53(86)87)78-56(88)43(68)30-39-16-20-41(82)21-17-39)63(95)77-49(32-40-18-22-42(83)23-19-40)59(91)75-47(29-35(3)4)61(93)81-55(37(6)8-2)65(97)74-46(66(98)99)15-12-28-71-67(69)70/h9-11,13-14,16-23,35-37,43-51,54-55,82-83H,7-8,12,15,24-34,68H2,1-6H3,(H,72,94)(H,73,96)(H,74,97)(H,75,91)(H,76,89)(H,77,95)(H,78,88)(H,79,92)(H,80,90)(H,81,93)(H,84,85)(H,86,87)(H,98,99)(H4,69,70,71)/t36-,37-,43-,44-,45-,46-,47-,48-,49-,50-,51-,54-,55-/m0/s1

Standard InChI Key:  HBJGGMQQUHUSAH-XUTCCZFNSA-N

Alternative Forms

  1. Parent:

    ALA4165601

    ---

Associated Targets(Human)

TNFSF11 Tclin Tumor necrosis factor ligand superfamily member 11 (138 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 1449.72Molecular Weight (Monoisotopic): 1448.6468AlogP: #Rotatable Bonds:
Polar Surface Area: Molecular Species: HBA: HBD:
#RO5 Violations: HBA (Lipinski): HBD (Lipinski): #RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: CX LogP: CX LogD:
Aromatic Rings: Heavy Atoms: QED Weighted: Np Likeness Score:

References

1. Liu C, Chen X, Zhi X, Weng W, Li Q, Li X, Zou Y, Su J, Hu HG..  (2018)  Structure-based development of an osteoprotegerin-like glycopeptide that blocks RANKL/RANK interactions and reduces ovariectomy-induced bone loss in mice.,  145  [PMID:29348072] [10.1016/j.ejmech.2018.01.022]

Source